Supplementary Table 7. Odds ratios for ischemic outcomes by region after additional adjustment for DOAC dose reduction

	Asian (n=245)	Non-Asian (n=1,730)	*P*
Composite outcome within 30 days			
Crude	0.58 (0.21–1.60)	0.75 (0.43–1.29)	0.67
Adjusted	0.66 (0.23–1.90)	0.95 (0.54–1.68)	0.55
Composite outcome within 90 days			
Crude	0.48 (0.18–1.27)	0.71 (0.44–1.14)	0.48
Adjusted	0.50 (0.18–1.39)	0.85 (0.52–1.39)	0.36
Major extracranial bleeding within 30 days			
Crude	0.32 (0.01–8.00)	0.79 (0.19–3.19)	0.62
Adjusted	0.28 (0.01–6.97)	1.05 (0.24–4.65)	0.46
Major extracranial bleeding within 90 days			
Crude	0.13 (0.01–2.64)	0.64 (0.17–2.44)	0.35
Adjusted	0.11 (0.01–2.26)	0.80 (0.20–3.25)	0.25
Vascular death within 30 days			
Crude	1.38 (0.27–7.12)	1.01 (0.39–2.63)	0.75
Adjusted	6.20 (0.31–122.98)	2.00 (0.63–6.32)	0.49
Vascular death within 90 days			
Crude	1.36 (0.26–7.06)	1.00 (0.48–2.09)	0.74
Adjusted	5.98 (0.30–119.45)	1.60 (0.70–3.67)	0.41

Data are presented as number (percentage), and adjusted odds ratio (95% confidence interval), computed on non-missing observations. The adjusted models include age, sex, National Institutes of Health Stroke Scale (NIHSS) score at admission, and direct oral anticoagulant (DOAC) dose reduction (yes/no).



Supplementary Figure 1. Distribution of mRS categories according to treatment arm at 90 days for Asian and non-Asian participants. mRS, modified Rankin Scale.